Hunkapiller Leaves as ABI Prepares For Phase Three and a Fuzzy Future | GenomeWeb

In one of his last public statements as president of Applied Biosystems, Mike Hunkapiller wrapped up a presentation on ABI’s finances in July by identifying two important trends in life sciences research.

“The first is the trend to systems biology, or integrated science, and the second is the trend towards targeted medicine,” Hunkapiller said. “At Applied Biosystems, we need to ensure that we continue to introduce products that support these research trends.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.